SCHEMBL6436077

SCHEMBL6436077

COc1ccc2c(c1)COc1c-2ccc2c(OC)cccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.46
CYP3A4 P08684 3/20 0.43
CYP1A1 P04798 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2E1 P05181 1/20 0.43
CYP2C8 P10632 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2A6 P11509 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP4B1 P13584 1/20 0.43
CYP2B6 P20813 1/20 0.43
CYP3A5 P20815 1/20 0.43
CYP2A7 P20853 1/20 0.43
CYP3A7 P24462 1/20 0.43
CYP2F1 P24903 1/20 0.43
CYP2C18 P33260 1/20 0.43
CYP2C19 P33261 1/20 0.43
CYP2J2 P51589 1/20 0.43
CYP4F2 P78329 1/20 0.43
CYP4F8 P98187 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6437588 0.81 KDM4E (0.46) RXRACYP3A4CYP1A2CYP2D6CYP2A6
SCHEMBL6440485 0.81 HSP90AA1 (0.43) RXRACYP3A4CYP1A2CYP2D6CYP2A6
SCHEMBL6439121 0.77 MAPT (0.39) CYP3A4CYP1A2CYP2D6MAPTKDM4E
SCHEMBL6436081 0.74 KDM4E (0.38) CYP3A4CYP1A2CYP2D6MAPTKDM4E
SCHEMBL6436723 0.73 MPO (0.36) CYP3A4MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL6440958 0.73 SMN1; SMN2 (0.38) CYP3A4CYP1A2CYP2D6MAPTKDM4E
SCHEMBL6438595 0.73 MAOB (0.41) MAPTKDM4EHPGDSMN1; SMN2NPC1
SCHEMBL2706914 0.73 SIRT2 (0.38) CYP3A4CYP1A2CYP2A6MAPTKDM4E
SCHEMBL6442254 0.73 HTT (0.40) RXRACYP3A4MAPTKDM4EHPGD
SCHEMBL6440506 0.72 ALDH1A1 (0.46) CYP3A4CYP2C9MAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453820-B1 SUBSTITUTED 6H-DIBENZO[C,H]CHROMENES AS ESTROGENIC AGENTS WYETH CORP (US) 2005-06-01 EP disclosed
EP-1453820-A1 SUBSTITUTED 6H-DIBENZO C,H]CHROMENES AS ESTROGENIC AGENTS Wyeth (US) 2004-09-08 EP disclosed
US-6723747-B2 ESTROGEN RECEPTOR MODULATORS USEFUL IN TREATING OR INHIBITING CONDITIONS, DISORDERS, OR DISEASE STATES AT LEAST PARTIALLY MEDIATED BY ESTROGEN DEFICIENCY OR EXCESS, OR WHICH MAY BE TREATED OR INHIBITED THROUGH USE OF ESTROGENIC AGENT WYETH 2004-04-20 US disclosed
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents WYETH 2003-09-18 US disclosed
WO-2003051863-A1 SUBSTITUTED 6H-DIBENZO[c,h]CHROMENES AS ESTROGENIC AGENTS WYETH (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176491-A1 Substituted 6H-DiBenzo[c,h]chromenes as estrogenic agents ESR2, ESR1, ESRRA RXRA 69/4885CYP3A4 215/4885CYP1A1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.